



Daniel M. Silver

Partner

T. 302-984-6331

F. 302-691-1260

dsilver@mccarter.com

McCarter & English, LLP

Renaissance Centre

405 N. King Street, 8th Floor

Wilmington, DE 19801-3717

www.mccarter.com

May 11, 2021

VIA CM/ECF

The Honorable Richard G. Andrews
U.S. District Court for the District of Delaware
J. Caleb Boggs Federal Building
844 North King Street
Room 6325, Unit 9
Wilmington, DE 19801-3555

Re: *In re Sitagliptin Phosphate ('708 & '921) Patent Litigation, C.A. Nos. 19-md-2902-RGA, 19-312-RGA, 19-313-RGA, 19-314-RGA, 19-319-RGA, 19-1489-RGA, 20-749-RGA, 20-815-RGA, 20-847-RGA, 20-949-RGA, 20-1099-RGA, & 20-1496-RGA, & 21-315-RGA*

Dear Judge Andrews,

As the court may recall from the *Markman* hearing, U.S. Patent No. 7,326,708 (the “‘708 Patent”) was the subject of an inter partes review. On May 7, 2021, the PTAB issued its final written decision confirming the patentability of all challenged claims. A copy of that decision is enclosed.

Respectfully submitted,

/s/ *Daniel M. Silver*

Daniel M. Silver (#4758)

cc: All Counsel of Record (via CM/ECF and E-Mail)